Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc (SMTI) specializes in advanced collagen-based solutions for surgical and chronic wound care, serving healthcare providers through clinically validated technologies. This hub provides investors and medical professionals with centralized access to official corporate developments.
Key Resources: Track FDA clearances for medical devices, quarterly earnings reports detailing commercialization progress, and strategic partnership announcements with healthcare distributors. All content is sourced directly from company filings and verified press releases.
Content Types Include: Product launch details for wound care innovations, financial performance updates, clinical study outcomes, and executive leadership changes. Materials are organized chronologically for historical analysis and trend identification.
Staying Informed: Bookmark this page or check regularly for unedited primary source materials about SMTI's market position in medical technology. Cross-reference with regulatory databases for complete context on product approvals.
Sanara MedTech (NASDAQ: SMTI) announced a significant leadership transition, appointing Seth Yon as President, CEO, and Board Director, effective September 15, 2025. Yon, currently serving as President and Chief Commercial Officer, will succeed Ron Nixon, who will continue as Executive Chairman.
Under Yon's various leadership roles since joining in 2018, Sanara achieved remarkable 53% compound annual net revenue growth over the past three fiscal years. His progression through the company included positions as Director of Sales, National Sales Director, VP of Commercial, and President of Commercial.
The appointment represents the culmination of a strategic initiative to strengthen senior leadership and position Sanara for future growth in surgical, chronic wound, and skin markets. Yon brings 27 years of industry experience, including previous roles at Iroquois Industrial Group, GreenerGrads, and Jostens, Inc.
Sanara MedTech (NASDAQ: SMTI), a medical technology company specializing in surgical, chronic wound, and skin markets, will participate in the Cantor Global Healthcare Conference at the New York Marriott Marquis from September 2-5, 2025.
Management will conduct a fireside chat presentation on September 3, 2025, at 2:45 p.m. ET. Presentation materials will be available on the company's investor relations website before the event, and a live audio webcast will be accessible in the "Events" section, with replay available post-conference.
Sanara MedTech (Nasdaq: SMTI) reported strong Q2 2025 financial results with net revenue increasing 28% to $25.8 million year-over-year. The company's Sanara Surgical segment showed significant improvement, generating $0.5 million in net income and $4.7 million in Segment Adjusted EBITDA for Q2 2025.
Key highlights include gross margin improvement to 93% and operating loss reduction to just $31,000 compared to $2.9 million in Q2 2024. The company announced plans to evaluate strategic alternatives for its Tissue Health Plus (THP) subsidiary, which reported a net loss of $2.5 million in Q2 2025. As of June 30, 2025, Sanara had $17.0 million in cash and $44.2 million in long-term debt.
Sanara MedTech (NASDAQ: SMTI), a medical technology company specializing in surgical, chronic wound, and skin markets, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day to discuss Q2 2025 results and conduct a Q&A session. Investors can access the call via toll-free number 888-506-0062 (access code: 132343) or through the company's website.
Sanara MedTech (Nasdaq: SMTI) has launched a pilot program through its subsidiary Tissue Health Plus (THP) for value-based wound care services. The program partners with a wound care provider group operating across six states to deliver at-home chronic wound care.
The THP technology platform will serve as the provider group's Wound Care Operating System, featuring the Co-Pilot software for standardizing patient encounters and treatment interventions. The platform includes two-way EMR integration to streamline administrative processes. The company aims to launch another pilot program with a payer in the second half of 2025.
Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound and skincare markets, has scheduled its first quarter 2025 financial results announcement for May 14, 2025 before U.S. markets open.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day to discuss results for the quarter ended March 31, 2025. Investors can join via phone (toll-free: 888-506-0062, international: 973-528-0011, access code: 490762) or webcast. A replay will be available through May 28, 2025 (replay numbers: 877-481-4010, international: 919-882-2331, passcode: 52308).
Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound and skincare markets, has announced its participation in the Planet MicroCap Showcase: VEGAS 2025. The event will be held at the Paris Hotel & Casino in Las Vegas from April 22-25, 2025.
Management will deliver their presentation on Wednesday, April 23, 2025, at 3:30 p.m. Pacific Time. Investors can access the presentation materials on the company's investor relations website prior to the event. A live audio webcast will be available under the 'Events' section, with a replay option available after the conference.
Sanara MedTech (SMTI) reported strong Q4 2024 financial results with net revenue increasing 49% year-over-year to $26.3 million. Full-year 2024 revenue grew 33% to $86.7 million.
Q4 highlights include:
- Gross profit rose 51% to $24.1 million with 91% margin
- Operating loss of $0.4 million compared to $0.2 million loss in Q4 2023
- Net loss of $1.7 million versus $0.3 million loss in Q4 2023
- Adjusted EBITDA of $0.9 million, up from $0.4 million
The growth was primarily driven by increased sales of soft tissue repair products, particularly CellerateRX Surgical and BIASURGE. The company plans to invest $7.5-10.0 million in Tissue Health Plus segment in H1 2025, with a pilot program launch expected in Q2. As of December 31, 2024, Sanara had $15.9 million cash and $30.5 million in debt obligations.
Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound and skincare markets, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 25, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day to discuss the results for the quarter and year ended December 31, 2024. Investors can join via phone (toll-free: 888-506-0062, international: 973-528-0011, access code: 904042) or watch the live webcast on the company's website. A replay will be available through April 08, 2025.
FAQ
What is the current stock price of Sanara Medtech (SMTI)?
What is the market cap of Sanara Medtech (SMTI)?
